Sertraline-induced reproductive toxicity in male rats: evaluation of possible underlying mechanisms

Ozlem Atli¹, Merve Baysal¹, Gozde Aydogan-Kilic², Volkan Kilic², Seyda Ucarcan², Burak Karaduman¹, Sinem Ilgin¹

This study was conducted to clarify the toxic effects of sertraline (SRT) on the reproductive system of male rats and to elucidate the underlying mechanisms. Rats were treated orally with SRT at doses of 5, 10, and 20 mg kg⁻¹ for 28 consecutive days. At the end of the treatment period, sperm concentration, sperm motility, and sperm morphology were investigated by computer-assisted sperm analysis system whereas sperm DNA damage was detected by comet assay. The oxidative status of the testes was investigated, and a histopathological examination was conducted. Serum testosterone, follicle-stimulating hormone (FSH), and luteinizing hormone (LH) levels were measured to determine the effects of SRT on the spermatogenesis process. One-way ANOVA, post-hoc Dunnett’s T3 test for the sperm comet assay, and post-hoc Tukey’s test for the others were performed for statistical analysis. The results showed that SRT caused an increase in sperm DNA damage and induced histopathological lesions in all groups treated with SRT. There was abnormal sperm morphology and increased malondialdehyde (MDA) in the 10 mg kg⁻¹ treatment group. More dramatic changes were observed in the 20 mg kg⁻¹ treatment group. Decreased sperm count was accompanied by a significant increase in abnormal sperm morphology, DNA damage, and degeneration in cellular-tubular structures. Serum LH and testosterone levels were elevated in the 20 mg kg⁻¹ treatment group. Decreased glutathione (GSH) and increased MDA were signs of enhanced oxidative stress (OS). In conclusion, SRT induced testicular toxicity in a dose-dependent manner and OS is suggested as a crucial mechanism.

Keywords: DNA damage; oxidative stress; reproductive toxicity; sertraline

INTRODUCTION

Infertility is defined as unsuccessful pregnancy resulting from regular and unprotected intercourse between couples during a 1-year period, and infertility incidence among couples has been calculated to be 15%.¹ Infertility etiology between couples comprises 40%–50% of women-only induced factors, 30% of men-only induced factors, and 20% of both men- and women-induced factors. Direct or indirect men-induced factors compose approximately 30%–50% of infertility cases.²,³ Varicocele, congenital anomalies, urogenital infections, endocrine illnesses, and immunological factors can be counted among the etiological factors causing infertility in men. Obesity, radiation, and weather also affect fertility in men.³ Repeated doses of exposed drugs may also cause infertility in men either directly by affecting the gonads or indirectly by affecting pituitary gonadotropins and causing changes in sperm parameters such as sperm count, mortality, and morphology.⁴,⁵

Selective serotonin reuptake inhibitors (SSRIs) are drugs that are used for short- and long-term treatment of mental illnesses. Most prevalent psychiatric illnesses are anxiety disorders, and SSRIs are the first-line drugs in the treatment of these disorders.⁶ Sertraline (SRT), one of the three commonly prescribed SSRIs,⁷ is used in the treatment of obsessive-compulsive disease, anxiety, and depression.⁸ During SSRI treatment, various central and peripheral nervous system-related hormonal and neurochemical changes occur, which are responsible for the adverse effects on the reproductive system.⁹ SSRIs are known to cause adverse sexual effects such as anorgasmia, erectile dysfunction, and decreased libido.¹⁰,¹¹

Previous studies have assessed sperm quality as a result of SSRI toxicity. Normal sperm morphology,¹²,¹³ sperm concentration,¹²,¹³ sperm motility¹²,¹³ were found decreasing, and abnormal sperm DNA fragmentation was induced¹²,¹³,¹⁵ in male patients under SSRI treatment including citalopram, escitalopram, fluoxetine, paroxetine, and SRT. However, the effects of SRT on the male reproductive system remain unclear. The present study investigated sperm parameters such as sperm morphology, motility, and concentration simultaneously with the affected hormone levels, oxidative stress (OS) parameters, DNA damage, and pathological conditions to provide more detailed information on the underlying mechanisms of SRT toxicity in the male reproductive system.

MATERIALS AND METHODS

Materials

SRT hydrochloride (C₁₅H₁₄ClN) was donated by the IE Ulagay-Menarini Group (Istanbul, Turkey). Testosterone, follicle-stimulating hormone (FSH), luteinizing hormone (LH), malondialdehyde (MDA),...
and glutathione (GSH) levels were determined using ELISA kits from Cusabio Biotech Co. Ltd. (Hubei, China).

**Animals**

Male Wistar rats weighing 200–250 g and aged 8 to 10-week-old were obtained from Anadolu University Research Center for Animal Experiments. The rats were housed in a room at a controlled temperature (24°C) under a 12-h light/12-h dark cycle (lights on at 08:00 am) with access to food and water ad libitum. Animals were acclimatized to the laboratory environment for at least 48 h before the experimental session. The experimental protocol was approved by the Local Ethical Committee on Animal Experimentation of Anadolu University, Eskisehir, Turkey (certificate number: 2014-33), in adherence with the National Institutes of Health Guidelines for the Use of Laboratory Animals.

**Experimental groups**

The rats were assigned randomly into the following treatment groups – control group: animals received distilled water by oral gavage per day (7 days per week) for 4 weeks (n = 8). 5 mg kg⁻¹ SRT-treated group: animals received 5 mg kg⁻¹ dose of SRT by oral gavage per day (7 days per week) for 4 weeks (n = 8). 10 mg kg⁻¹ SRT-treated group: animals received 10 mg kg⁻¹ dose of SRT by oral gavage per day (7 days per week) for 4 weeks (n = 8). 20 mg kg⁻¹ SRT-treated group: animals received 20 mg kg⁻¹ dose of SRT by oral gavage per day (7 days per week) for 4 weeks (n = 8). In previous studies, the reproductive toxicity of SRT has not been investigated within a dose-response relationship in rats. For this reason, the doses of SRT were determined according to the previous studies investigating SRT-induced antidepressant effects to obtain a dose-response relationship in therapeutic concentrations of SRT in rats, and these doses were in accordance with the guidelines extrapolating human doses to animal doses. All drugs were administered at a volume of 1 ml per 100 g body weight by dissolving in distilled water. The treatment period was in accordance with the guideline.

At the end of 4 weeks, the animals were anesthetized by intraperitoneal injection of 1.5 g kg⁻¹ urethane. Blood samples for hormonal analysis (FSH, LH, and testosterone) were collected from the right ventricle of the animals via a syringe. The animals were euthanized via withdrawal of large amounts of blood from the heart.

Testicular and epididymis tissues were removed. The left testis and epididymis were cleaned of blood in a phosphate buffer solution (PBS) (composition: NaCl: 8 g l⁻¹, KCl: 0.2 g l⁻¹, KH₂PO₄: 0.2 g l⁻¹ and Na₂HPO₄: 1.14 g l⁻¹ at pH 7.4) and weighed. The left epididymis was used to determine the levels of GSH and MDA. The right testis was cleaned of blood and other contaminants in PBS and fixed for histological examination. The cauda of the right epididymis was used for sperm parameters.

**Collection and evaluation of sperm samples**

Spermatozoa obtained from the right epididymis immediately after euthanizing rats were placed in a Petri dish containing DMEM/Hams F-12 at 37°C. The cauda epididymis was transferred to a new Petri dish with 1 ml of the same medium, and blood vessels and fat tissue were removed. Approximately 0.5 cm of the cauda epididymis was removed and placed in another Petri dish containing 1 ml of the same medium, and spermatozoa were allowed to swim out of the tissue for 1 min.

Assessment of sperm concentration and motility

Five microliters of a concentrated spermatozoa cloud was collected and placed on a Leja slide (Leja Products BV, Nieuw Vennep, The Netherlands). The Leja slide was placed onto a temperature controlled stage of the Nikon E200 microscope (set at 37°C). A negative phase contrast objective (4×) in conjunction with a phase contrast condenser was used to determine sperm motility and concentration via a motility/concentration module of the Sperm Class Analyzer²⁷ (SCA), version 5.4.0.1 (Microptic Automatic Diagnostic System, Barcelona, Spain), at 50 frames s⁻¹. The data were collected by capturing images with a digital camera (Basler AG, Ahrensburg, Germany). For the sperm motility evaluation, a total of eight fields were captured with the SCA system, and 200 motile spermatozoa were counted and analyzed as recommended by the World Health Organization.²⁶

Assessment of sperm morphology

Fresh sperm smears were prepared for morphometric analysis by placing 5 µl of the fresh semen on the clear end of a frosted slide by dragging the drop across the slide. The smears were allowed to air dry before staining. Three semen smears were prepared and stained with Spermblue²⁸ (Microptic Automatic Diagnostic System, Barcelona, Spain) according to Van der Horst and Maree (2009).²⁵ Stained slides were used to perform a morphology evaluation using a morphometry module of SCA version 5.4.0.1 software.

The machine was equipped with a Nikon Eclipse model 50i (Nikon Corporation, Tokyo, Japan) microscope with a 60× bright-field objective and a video camera (Basler, AG, Ahrensburg, Germany). A total of 200 sperms/animal were analyzed randomly. The morphometric parameters of the head and tail were determined, and abnormal sperms were detected according to previous criteria.²⁸–³² Sperms with a banana-shaped head, amorphous head, and bent neck and two-headed and headless sperms were counted for head abnormalities whereas sperms with a bent tail and broken tail were counted for tail abnormalities (Figure 1).

Sperm comet assay

Fresh microscope slides were covered with 1% normal melting point agarose in Ca²⁺- and Mg²⁺-free PBS. The sperm sample (10 µl) containing 1 × 10⁶ sperm ml⁻¹ was suspended in 75 µl of 1% (w/v) low melting point agarose. Then, 85 µl of this suspension was applied to the surface of a microscope slide (precoated with 1% normal melting point agarose) to form a microgel and allowed to set at 4°C for 5 min. Slides were dipped in cell lysis buffer (2.5 mol l⁻¹ NaCl, 100 mmol l⁻¹ EDTA, 10 mmol l⁻¹ Tris-HCl, pH 10.0, containing 1% Triton X-100 added just before use, and 40 mmol l⁻¹ dithiothreitol) for 24 h at room temperature. Following the initial lysis, proteinase K was added to the lysis solution (0.5 mg ml⁻¹), and an additional lysis was performed at 37°C for 24 h. After cell lysis, all slides were washed three times with deionized water at 10 min intervals to remove salt and detergent from the microgels. Slides were placed in a horizontal electrophoresis unit and were allowed to equilibrate for 20 min with running buffer (500 mmol l⁻¹ NaCl, 100 mmol l⁻¹ Tris-HCl and 1 mmol l⁻¹ EDTA, pH 9.0) before electrophoresis (0.60 V cm⁻¹, 250 mA) for 30 min. After electrophoresis, slides were then neutralized with 0.4 mol l⁻¹ Tris (pH 7.5), stained with SYBR Green I (1:10,000) (Sigma-Aldrich, Taufkirchen, Germany) for 1 h and covered with cover slips.

**Biochemical analysis**

**Determination of serum FSH, LH, and testosterone levels**

After drawing blood for 30 min to allow clotting, blood samples from rats were centrifuged for 15 min (at 4°C and at 1000 g), and serum was separated. The hormonal analyses were performed using commercially available kits according to the manufacturer’s instructions.

**Determination of GSH and MDA levels in testes**

The left testis was divided into equal parts and stored at -20°C after freezing in liquid nitrogen. The GSH and MDA levels in the testis were
Sertraline-induced reproductive toxicity in male rats
O Atli et al

Effects of sertraline treatment on sperm morphology in rats

Effects of sertraline treatment on testis and epididymis weights in rats

Effects of sertraline treatment on sperm concentration and motility in rats

Effects of sertraline treatment on sperm morphology in rats

All data were expressed as mean±s.e. *Significant differences when compared with control group (P<0.05); **Significant differences when compared with control group (P<0.001). s.e.: standard error; BW: body weight; C: control group; SRT-5: 5 mg kg⁻¹ sertraline-treated rats for 28 days group; SRT-10: 10 mg kg⁻¹ sertraline-treated rats for 28 days group; SRT-20: 20 mg kg⁻¹ sertraline-treated rats for 28 days group.
10 (P < 0.001) and 20 mg kg⁻¹ SRT-administered groups (P < 0.001) compared to the control. Among the SRT-administered groups, the percentages of the sperm abnormalities were increased in the 10 (P = 0.002) and 20 mg kg⁻¹ SRT-administered groups (P < 0.001) compared to the 5 mg kg⁻¹ SRT-administered group (Table 1).

These abnormalities were found to occur more often in the tail, represented by bent tail and broken tail (Figure 1) in the 10 and 20 mg kg⁻¹ SRT-administered groups at 12.79% and 19.69%, respectively. In addition, the percentages of sperm head abnormalities including banana-shaped head, amorphous head, bent neck, and two-headed and headless sperms (Figure 1) were determined as 10.44% and 13.19% in the 10 and 20 mg kg⁻¹ SRT-administered groups, respectively.

**Sperm DNA damage**

The results expressed as tail moment (Extent tail moment: tail length × tail% DNA/100) for sperms exposed to various doses of SRT or in the control group are shown in Figure 2. One-way ANOVA revealed a difference among the groups (F₁,₁₉₆ = 131.862; P < 0.05). All the experimental groups showed an increase in sperm DNA damage. Exposure to 5 and 10 mg kg⁻¹ of SRT increased the tail moment by approximately 49.70% and 86.35%, respectively. There was no significant difference between these groups in tail moment. However, according to post-hoc comparisons (Dunnett’s T3 test), the 20 mg kg⁻¹ treatment resulted in a dramatic increase in tail moment (over 5-fold compared to control, over 3-fold compared to the 5 mg kg⁻¹ SRT-administered group, and over 2-fold compared to the 10 mg kg⁻¹ SRT-administered group) (P < 0.05).

**Effects of SRT treatment on the serum hormone levels in rats**

In comparing serum FSH levels of the groups, no significant differences were observed among the groups (Table 2).

According to LH levels, one-way ANOVA indicated a difference among groups (F₁,₁₉₆ = 36.643; P < 0.001). Serum LH levels showed an increase in the 20 mg kg⁻¹ SRT-administered group in comparison with the control, 5 mg kg⁻¹ and 10 mg kg⁻¹ SRT-administered groups (P < 0.001) (Table 2).

In comparing serum testosterone levels of the groups, a difference was obtained (F₁,₁₉₆ = 5.826, P = 0.005). Serum testosterone levels showed an increase in the 20 mg kg⁻¹ SRT-administered group in comparison with the control (P = 0.023), 5 mg kg⁻¹ (P = 0.005) and 10 mg kg⁻¹ SRT-administered groups (P = 0.045) (Table 2).

**Effects of SRT treatment on GSH and MDA levels in rats**

There was a difference in GSH levels compared among groups (F₁,₁₉₆ = 10.838; P < 0.001). The testicular GSH levels in the 20 mg kg⁻¹ SRT-administered group decreased in comparison with the control group (P < 0.001). In addition, it was shown that GSH levels of the 20 mg kg⁻¹ SRT-administered group were also decreased compared to those of 5 mg kg⁻¹ (P = 0.002) and 10 mg kg⁻¹ SRT-administered groups (P = 0.027) (Table 2).

One-way ANOVA revealed a difference according to the MDA levels of the groups (F₁,₁₉₆ = 18.121; P < 0.001). MDA levels increased in the 5 mg kg⁻¹ (P = 0.003), 10 mg kg⁻¹ (P < 0.001), and 20 mg kg⁻¹ SRT-administered groups (P < 0.001) compared to the control group. The MDA levels in the 5 mg kg⁻¹ SRT-administered group were also found to be lower compared to those of the 20 mg kg⁻¹ SRT-administered groups (P = 0.014) (Table 2).

**Histological analysis**

Figure 3 illustrates the histopathological changes in the seminiferous tubules and spermatogenic series of animals that were treated with different doses of SRT. The testicular structure of the control rats was normal. The seminiferous tubules appeared uniform in size and shape with regularly arranged rows of spermatogenic series and usual structure of the germ cells (Figure 3a and 3e). There was a slight degeneration in the seminiferous tubules of the 5 mg kg⁻¹ SRT-administered group. Vacuolization of Sertoli cells, hypocellularity, and widened gaps between cells of the spermatogenic series were observed (Figure 3b and 3f). Swelling of the cells with an increased number of vacuoles was characterized in the 10 mg kg⁻¹ SRT-administered group. There was a deformation in the cellular and tubular architecture. Seminiferous tubules showed a single layer of basal spermatogonia as a result of a reduction of cells in the spermatogenic series (Figure 3c and 3g). The 20 mg kg⁻¹ SRT-administered group showed tubular and cellular atrophy, loss of intact germinal layer, and spermatogenesis as a result of dramatic degeneration in germ cells. Pyknotic nuclei were observed along with karyolysis and cellular lysis. Necrosis, vacuolization, and disruption of the seminiferous epithelium were also observed (Figure 3d, 3h, and 3i). Leydig cells also showed a damaged nucleus, pyknotic nuclei, and apoptotic bodies (Figure 3j). Johnsen’s scores and semiquantitative comparison of pathology at the cellular level are shown in Table 3.

**DISCUSSION**

In the present study, we only evaluated the reproductive toxic effect of SRT in male rats independent of other risk factors related to infertility and in repeated pharmacological doses. The results have shown that SRT decreased the sperm concentration and normal sperm morphology, increased sperm DNA damage, and induced
Table 2: Effects of sertraline on circulating hormone levels and oxidative stress markers of male rats

|                | Oxidative stress markers | Hormone levels |
|----------------|--------------------------|----------------|
|                | MDA (µmol m⁻³) | GSH (µmol l⁻¹) | FSH (IU l⁻¹) | LH (mg dl⁻¹) | Testosterone (IU l⁻¹) |
|----------------|---------------------|----------------|-------------|-------------|-----------------------|
| Control; normal sperm morphology | 424.03±30.24 | 32.92±1.01 | 47.00±3.15 | 7.22±0.67 | 3.13±0.17 |
| SRT-5; slight vacuolation of sertoli cells | 543.78±22.89** | 29.96±0.92* | 48.17±2.09 | 7.38±0.95* | 2.94±0.12* |
| SRT-10; severe vacuolation and reduction of cells in the spermatogenic series | 590.58±23.51** | 27.68±1.47* | 49.17±1.02 | 7.84±0.31* | 3.55±0.30* |
| SRT-20; slight deformation of cellular architecture | 690.83±31.34** | 21.15±1.69** | 56.45±2.64 | 10.40±0.24** | 4.68±0.32* |

All data were expressed as means±s.e. *Significant differences when compared with control group (P<0.05). **Significant differences when compared with control group (P<0.001). C: control group; SRT-5: 5 mg kg⁻¹ sertraline-treated rats for 28 days group; SRT-10: 10 mg kg⁻¹ sertraline-treated rats for 28 days group; SRT-20: 20 mg kg⁻¹ sertraline-treated rats for 28 days group; s.e.: standard error; MDA: malondialdehyde; GSH: glutathione; FSH: follicle-stimulating hormone; LH: luteinizing hormone.

Table 3: Johnsen's scores and semiquantitative comparison of pathology at the cellular level

|                | Johnsen's score (mean±s.e.) | Spermatogonial swelling | Cytoplasmic vacuolation | Deformation of cellular architecture |
|----------------|-----------------------------|-------------------------|------------------------|-------------------------------------|
| Control; normal sperm morphology | 9.58±0.50 | - | - | - |
| SRT-5; slight vacuolation of sertoli cells | 9.37±0.49 | + | + | + |
| SRT-10; severe vacuolation and reduction of cells in the spermatogenic series | 8.66±0.48* | ++ | +++ | + |
| SRT-20; slight deformation of cellular architecture | 7.83±0.76* | +++ | +++ | +++ |

*Significant differences when compared with control group (P<0.05). In terms of sperm concentration, motility, and morphology, which we evaluated in our study, sperm concentration and normal sperm morphology decreased in the 20 mg kg⁻¹ SRT-administered group. Case reports that support our results draw attention to decreases in sperm concentration, motility, and normal sperm morphology in patients with SRT treatment.12,13,38

The endocrine balance between the hypothalamic–pituitary–testicular axis controls spermatogenesis.39,40 Gonadotropin-releasing hormone (GnRH) released into the hypothalamic–hypophyseal portal circulation stimulates the release of FSH and LH gonadotropins into the blood circulation. FSH mediates spermatogenesis by binding to its localized receptors, and LH mediates spermatogenesis-stimulating testosterone release by affecting Sertoli and peritubular cells of the seminiferous tubules by binding to its receptors in Leydig cells.39–41 In our study, the increased serum LH and testosterone levels were observed in the high-dose SRT-administered group. There were very limited data related to the effects of SRT treatment in rats on the hormones mediating spermatogenesis, which showed an increase in FSH and decreased testosterone levels without any change in LH levels.3 SSRIs were also shown to affect these hormones but not in a particular manner.3,42,43 GnRH secretion regulates several neurotransmitters, such as serotonin, norepinephrine, and dopamine.42,43 In immortalized GnRH neural cells, serotonin stimulates GnRH release.43 Hence, treatment with SSRIs could affect GnRH secretion. However, studies have emphasized that the effect of serotonin could be minor compared to other neurotransmitters histopathological changes in testicular tissue. These toxic effects induced by SRT have been accompanied by decreased tissue GSH level, increased MDA, and the changes in serum LH and testosterone levels, which play a role in the spermatogenesis process.

Male factor infertility is usually diagnosed through the evaluation of such parameters as sperm concentration, sperm motility, and sperm morphology.45 In terms of sperm concentration, motility, and morphology, which we evaluated in our study, sperm concentration and normal sperm morphology decreased in the 20 mg kg⁻¹ SRT-administered group. Case reports that support our results draw attention to decreases in sperm concentration, motility, and normal sperm morphology in patients with SRT treatment.12,13,38

Figure 3: (a–d) Cross section of the testis of control and experimental group rats (L: lumen; ss: spermatogenic series; sp: spermatozoa). (a) Control; normal aspect of the seminiferous tubules containing cells of the spermatogenic series and spermatogonia in the lumen; (b) SRT-5 (5 mg kg⁻¹ sertraline-treated rats for 28 days group); seminiferous tubule showing slight degeneration with wide gaps between neighboring cells (arrowheads); (c) SRT-10 (10 mg kg⁻¹ sertraline-treated rats for 28 days group); seminiferous tubule showing slight degeneration with wide gaps between neighboring cells (arrowheads); (d) SRT-20 (20 mg kg⁻¹ sertraline-treated rats for 28 days group); seminiferous tubule showing single layer of basal spermatogonia (arrowheads); (e–j) High magnification of cells of the spermatogenic series in control and experimental group rats; (e) control; spermatogenic series (ss) with normal appearance of cells; (f) SRT-5; slight vacuolation of sertoli cells (arrowheads), expanded intercellular spaces (arrows); (g) SRT-10; Swelling of cells with increased number of small vacuoles (arrowheads), deformation of cellular architecture (+); (h and i) SRT-20; deformation of basal lamina (arrowhead), degenerating germ cells showing nuclear pyknosis (arrows), karyolysis (k) and cellular lysis (ly), multiple extracellular vacuoles (v), necrotic (n) germ cells sloughed out into the lumen (L) of seminiferous tubules (arrow), disintegrated epithelium (+); (j) SRT-20; Leydig cells with damaged nucleus (long arrow), pyknotic nuclei (arrowheads), and apoptotic bodies (arrow). Scale bars = 50 µm for (a–d) and 20 µm for (e–j).
Male infertility is associated with increased DNA damage in spermatozoa. DNA damage can occur independently of standard semen parameters, and increased sperm DNA fragmentation is correlated with infertility. For this reason, measurement of DNA damage in spermatozoa is very important to evaluate the reproductive toxic effects of chemicals. The comet assay is a sensitive method used in the measurement of DNA strand breaks. This assay, sperm with high DNA strand breaks show intense comet tail and increased comet tail length due to the increased DNA fragmentation. According to the results of our study, sperm DNA damage increased with SRT treatment, depending on dose. Consistent with our results, it has been observed that SRT treatment increases sperm DNA damage in patients with depression and in patients with premature ejaculation. Moreover, in various experimental models in which the genotoxic effects of SRT were investigated, different results have been obtained. SRT was found to increase DNA damage in lymphocyte comet and micronucleus assays in patients and sister chromid exchange frequencies in rats, which indicates a possible genotoxicity of the drug and is also described as nongenotoxic in vitro test batteries.

Abnormal spermatozoa percentage and structural abnormalities (head-tail attachments, incomplete acrosomal development, and sperm cytoskeleton abnormalities) are important indicators of a defective spermatozoa production, maturation and infertility. It is known that even if sperm concentration or motility is normal, a morphological abnormality may be the one and only factor reflecting the fertilization potential. Male subjects are considered to be usually infertile when sperm cell abnormalities were determined as >10%. According to our morphological evaluation, abnormal sperm cells were increased resulting in both head and tail abnormalities in the 10 and 20 mg kg\(^{-1}\) SRT-administered groups (which occurred in a dose-dependent manner). It is important to emphasize that tail abnormalities, which are known to have a positive correlation with infertility, were significantly increased with SRT treatment. Furthermore, abnormal spermatozoa morphology is also associated with increases in DNA fragmentation and reactive oxygen species (ROS) overproduction. Trivedi et al. (2010) suggested that sperm DNA damage may lead to abnormalities in the sperm head, and the performance of the sperm comet assay along with the sperm head morphological evaluation is essential to identify and evaluate germ cell toxicants. Therefore, our study, in which the sperm comet assay was performed along with the sperm morphological evaluation, indicated the potential of SRT as a possible germ cell toxicant.

OS is considered one of the most important factors in the etiology of male infertility. Testicular tissue and spermatozoa are very sensitive to ROS and lipid peroxidation. The vulnerability of testicular tissue to OS is associated with sperm membrane, which contains high levels of polyunsaturated fatty acids and has a restricted antioxidant defense system. Herein, it is possible to associate the decreased sperm concentration and normal sperm morphology obtained from our study with OS in the testicles induced by SRT. Clinical research has shown that ROS cause a reduction in sperm count, sperm motility, and normal sperm morphology. In addition, it is possible to associate the dose-dependent sperm DNA damage observed in the SRT groups with the burst of free radicals. It is also known that lipid peroxides may interact with DNA and can cause strand breaks and DNA fragmentation. In the present study, MDA was increased depending on the dose in the 10 and 20 mg kg\(^{-1}\) treatment groups. The GSH dependent antioxidant defense system was of major importance at this point. A decreased GSH level in the 20 mg kg\(^{-1}\) treatment group was a sign of effort to overcome the oxidative imbalance.

Prolonged OS in testicles may cause important histopathological changes in the testis structure. Free radicals disrupt the membrane integrity in mammalian testicles, which may result in testicular atrophy and seminiferous tubule degeneration. Histopathology of the testes showed degeneration with an increasing severity particularly at the doses of 10 and 20 mg kg\(^{-1}\). Damage, including germinal cell degeneration, seminiferous tubules with atrophy, extracellular vacuoles, and reduction of cells in spermatogenic series, was observed in the testicular tissue and was especially apparent in our high-dose SRT group. Pyknosis, membrane bound vesicles (apoptotic bodies), and necrosis were observed in spermatogenic series and in Leydig cells in 20 mg kg\(^{-1}\) SRT-treated animals. In a previous study, SRT-associated toxicity was attributed to the mitochondrial dysfunction in the liver of rats. This dysfunction disrupts ATP generation and results in structural disorganization, apoptotic, necrotic, and necrotic cell death. Our findings revealed that the testes of the SRT-treated rats are likely to be found within similar conditions. Together with the OS induced by SRT in the testicle, it is possible to associate degenerative findings detected in testicular tissue with the elevated serum LH levels. Some previous studies suggest that an increase in the serum LH level may cause degeneration of the germinal cells in rats and mice.

Another important point that must be noted is that the excess levels or absence of serotonin may cause disorders in sperm parameters. Injecting serotonin to adult rats systemically has been reported to cause testicular atrophy, damage to spermatogenesis, and suppression of steroidogenesis. Serotonergic receptors, which are located at the hypothalamic–pituitary–testicular axis, mediate the negative effects of SSRIs on sperm parameters. It is alleged that increasing serotonin in the hypothalamus can cause dysregulation of this axis. SRT-induced reproductive effects can also be attributed to the increased serotonin levels.

According to the results of our study, induced OS and altered LH and testosterone levels with SRT administration adversely affected the sperm parameters by reducing sperm concentration and increasing abnormal sperm morphology and sperm DNA damage and caused damage in normal testicular morphology in rats. Hence, it can be suggested that the mechanism of SRT toxicity in the male reproductive system arises because of enhanced OS and altered hormonal status. In the future, testicular toxicity and the potential fertility level in patients treated with SRT should be examined in clinical studies. Further studies are needed to identify the effects of other SSRIs, which are frequently prescribed, on male fertility and on the conditions comprising these stress conditions. It is also necessary to clarify how SSRIs affect spermatogenesis in future research. In addition, health-care providers should give consideration to the potential adverse effects of SSRIs drugs in patients of reproductive age.

**AUTHOR CONTRIBUTIONS**

OA conceived of the study, carried out the experimental design, drafted the manuscript, participated in animal handling and dissection.
collection and evaluation of sperm samples, assessment of sperm motility, sperm morphology, biochemical assays, evaluation of the results, and statistical analysis. MB participated in animal handling and dissection, collection of sperm samples, assessment of sperm motility, sperm morphology, and biochemical assays. GAK participated in sperm comet assay, histopathological analysis, statistical analysis, and evaluation of the results. SU participated in animal handling and dissection, sperm comet assay, and histopathological analysis. BK participated in animal handling, dissection, and biochemical assays. SI carried out the experimental design and coordination, participated in animal handling and dissection, collection and evaluation of sperm samples, assessment of sperm motility, sperm morphology, biochemical assays, evaluation of the results and helped draft the manuscript. All authors read and approved the final manuscript.

COMPETING INTERESTS
All authors declare no competing interests.

ACKNOWLEDGMENTS
This study was supported by the Anadolu University Scientific Research Projects Commission under the grant no. 1404S128.

REFERENCES
1 Mehrabian F, Jafari M, Akbartabar Toori M, Sadeghi H, Joodi B, et al. Effects of date palm pollen (Phoenix dactylifera L.) and Astragalus ovatus on sperm parameters and sex hormones in adult male rats. Iran J Reprod Med 2014; 12: 705–12.
2 Kaya Z, Sogut E, Cayli S, Suren M, Arici S, et al. Evaluation of effects of repeated sevoflurane exposure on rat testicular tissue and reproductive hormones. Inhal Toxicol 2013; 25: 192–8.
3 Erdemir F, Alligian D, Firat F, Markoc F, Parlatkas BS, et al. The effect of sertraline, paroxetine, fluoxetine and escitalopram on testicular tissue and oxidative stress parameters in rats. Int Braz J Urol 2014; 40: 100–8.
4 Alonso V, Linares V, Bellés M, Albina ML, Sivent JJ, et al. Sulphasalazine induced oxidative stress: a possible mechanism of male infertility. Reprod Toxicol 2009; 27: 25–40.
5 Olayemi FO. A review on some causes of male infertility. Afr J Biotechnol 2010; 9: 2834–42.
6 Bystrynitsky A, Khalisa SS, Cameron ME, Schifman J. Current diagnosis and treatment of anxiety disorders. Pharm Ther 2013; 38: 30–57.
7 Sanchez C, Reines EH, Montgomery SA. A comparative review of escitalopram, paroxetine, and sertraline: are they all alike? Int Clin Psychopharmacol 2014; 29: 185–96.
8 Davies SJ, Mulsant BH, Flint AJ, Meyers BS, Rothschild AJ, et al. SSRI-antipsychotic combination in psychotic depression: sertraline pharmacokinetics in the presence of olanzapine, a brief report from the STOP-PD study. Hum Psychopharmacol 2016; 31: 252–5.
9 Lu S, Zhao Y, Hu J, Li X, Zhang H, et al. Combined use of phosphodiesterase-5 inhibitors and selective serotonin reuptake inhibitors for temporary ejaculation failure in couple undergoing assisted reproductive technologies. Fertil Steril 2009; 91: 1806–8.
10 Attia SM, Bakheet SA. Citalopram at the recommended human doses after long-term treatment is genotoxic for male germ cell. Food Chem Toxicol 2013; 53: 281–5.
11 Csoka AB, Shikpo S. Persistent sexual side effects after SSRI discontinuation. Psychother Psychosom 2006; 75: 187–8.
12 Akasheh G, Sirati L, Kamran AR, Sepehrmanesh Z. Comparison of the effect of sertraline with behavioral therapy on semen parameters in men with premature ejaculation. Urology 2014; 83: 800–4.
13 Safarinejad MR. Sperm DNA damage and semen quality improvement after treatment with selective serotonin reuptake inhibitors detected using semen analysis and sperm chromatin structure assay. J Urol 2008; 180: 2124–8.
14 Koyuncu H, Serefgolu EC, Yencilek E, Atalay H, Akbas NB, et al. Escitalopram treatment for premature ejaculation has a negative effect on semen parameters. Int J Impot Res 2011; 23: 257–61.
15 Tanrikut C, Feldman AS, Altemus M, Paduch DA, Schlegel PN. Adverse effect of paroxetine on sperm. Fertil Steril 2010; 94: 1021–6.
16 National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Guide for the Care and Use of Laboratory Animals.

Asian Journal of Andrology
Evaluation of the spermicidal and et al. 2014; in vivo

Kumar S, Behari J, Sisodia R. Influence of electromagnetic fields on reproductive system of male rats. Int J Radiat Biol 2013; 89: 147–54.

Lu Z, Wang L, Zhou R, Qiu Y, Yang L, et al. Evaluation of the spermicidal and contraceptive activity of platycodon D, a saponin from Platycodon grandiflorum. PLoS One 2013; 8: e82068.

Ahmed MA. Amelioration of nandrolone decanoate-induced testicular and sperm toxicity in rats by taurine: effects on steroidogenesis, redox and inflammatory cascades, and intrinsic apoptotic pathway. Toxicol Appl Pharmacol 2015; 282: 285–96.

Namejo RC, Khan S, Patel RS, Shera FY, Trivedi PP, et al. Pre-pubertal exposure of cytarabine-induced testicular atrophy, impaired spermatogenesis and germ cell DNA damage in SD rats. Toxicol Mech Methods 2014; 24: 703–12.

Bozkurt G, Abay E, Ates I, Karabogaz G, Ture M, et al. Clastogenicity of selective serotonin-reuptake inhibitors. Mutat Res 2004; 558: 137–44.

Battal D, Aktas A, Sungur MA, Kadioglu E, Eker ED, et al. In vivo genotoxicity assessment of sertraline by using alkaline comet assay and the cytokinesis-block micronucleus assay. Basic Clin Pharmacol Toxicol 2013; 11: 339–46.

Davies TS, Kluwe WM. Preclinical toxicological evaluation of sertraline hydrochloride. Drug Chem Toxicol 1998; 21: 521–37.

Agarwal A, Turda E, Sharma R. Relationship amongst teratozoospermia, seminal oxidative stress and male infertility. Reprod Biol Endocrinol 2014; 27: 12–45.

Menkvedt R, Halleboom CA, Rhennev JP. Measurement and significance of sperm morphology. Asian J Androl 2011; 13: 59–68.

Saba BA, Oridupa OA, Oyeyemi MO, Osanyigbe OD. Spermatozoa morphology and characteristics of male Wistar rats administered with ethanolic extract of Lagenaria siceraria. Afr J Biotechnol 2009; 8: 1170–5.

Agarwal A, Said TM. Oxidative stress, DNA damage and apoptosis in male infertility: a clinical approach. BJU Int 2005; 95: 503–7.

Wright C, Milne S, Leeson H. Sperm DNA damage caused by oxidative stress: a clinical approach. Reprod Biomed Online 2014; 28: 684–703.

Trivedi PP, Kushwaha S, Tripathi DN, Jena GB. Evaluation of male germ cell toxicity in rats: correlation between sperm head morphology and sperm comet assay. Mutat Res 2010; 703: 115–21.

Atken RJ, Roman SD. Antioxidant systems and oxidative stress in the testes. Oxid Med Cell Longev 2008; 1: 15–24.

Aktekin G, Dogru-Abbasoglu S, Kucukkergin C, Kadioglu A, Ozdemirler-Erata G, et al. Mystery of idiopathic male infertility: is oxidative stress an actual risk? Fertil Steril 2013; 99: 1211–5.